No biomarker
|
Thyroid Gland Medullary Carcinoma
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
cabozantinib capsule Sensitive: A1 - Approval
|
cabozantinib capsule Sensitive: A1 - Approval
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
selpercatinib Sensitive: A1 - Approval
|
selpercatinib Sensitive: A1 - Approval
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
vandetanib Sensitive: A1 - Approval
|
vandetanib Sensitive: A1 - Approval
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
pralsetinib Sensitive: A1 - Approval
|
pralsetinib Sensitive: A1 - Approval
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
dacarbazine Sensitive: A2 - Guideline
|
dacarbazine Sensitive: A2 - Guideline
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
denosumab Sensitive: A2 - Guideline
|
denosumab Sensitive: A2 - Guideline
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
cabozantinib tablet Sensitive: A2 - Guideline
|
cabozantinib tablet Sensitive: A2 - Guideline
|
TMB-H
|
Thyroid Gland Medullary Carcinoma
|
TMB-H
|
Thyroid Gland Medullary Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
cabozantinib capsule Sensitive: A2 - Guideline
|
cabozantinib capsule Sensitive: A2 - Guideline
|
RAS mutation
|
Thyroid Gland Medullary Carcinoma
|
RAS mutation
|
Thyroid Gland Medullary Carcinoma
|
cabozantinib capsule Sensitive: A2 - Guideline
|
cabozantinib capsule Sensitive: A2 - Guideline
|
KRAS mutation
|
Thyroid Gland Medullary Carcinoma
|
KRAS mutation
|
Thyroid Gland Medullary Carcinoma
|
cabozantinib capsule Sensitive: B - Late Trials
|
cabozantinib capsule Sensitive: B - Late Trials
|
NRAS mutation
|
Thyroid Gland Medullary Carcinoma
|
NRAS mutation
|
Thyroid Gland Medullary Carcinoma
|
cabozantinib capsule Sensitive: B - Late Trials
|
cabozantinib capsule Sensitive: B - Late Trials
|
KRAS mutation
|
Thyroid Gland Medullary Carcinoma
|
KRAS mutation
|
Thyroid Gland Medullary Carcinoma
|
cabozantinib capsule Sensitive: B - Late Trials
|
cabozantinib capsule Sensitive: B - Late Trials
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
TPX-0046 Sensitive: C2 – Inclusion Criteria
|
TPX-0046 Sensitive: C2 – Inclusion Criteria
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
BOS-172738 Sensitive: C2 – Inclusion Criteria
|
BOS-172738 Sensitive: C2 – Inclusion Criteria
|
RET V804*
|
Thyroid Gland Medullary Carcinoma
|
RET V804*
|
Thyroid Gland Medullary Carcinoma
|
pralsetinib Sensitive: C3 – Early Trials
|
pralsetinib Sensitive: C3 – Early Trials
|
RET C634*
|
Thyroid Gland Medullary Carcinoma
|
RET C634*
|
Thyroid Gland Medullary Carcinoma
|
pralsetinib Sensitive: C3 – Early Trials
|
pralsetinib Sensitive: C3 – Early Trials
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
pralsetinib Sensitive: C3 – Early Trials
|
pralsetinib Sensitive: C3 – Early Trials
|
RET C634R
|
Thyroid Gland Medullary Carcinoma
|
RET C634R
|
Thyroid Gland Medullary Carcinoma
|
sorafenib Sensitive: C3 – Early Trials
|
sorafenib Sensitive: C3 – Early Trials
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
sorafenib Sensitive: C3 – Early Trials
|
sorafenib Sensitive: C3 – Early Trials
|
RET V804M
|
Thyroid Gland Medullary Carcinoma
|
RET V804M
|
Thyroid Gland Medullary Carcinoma
|
selpercatinib Sensitive: C3 – Early Trials
|
selpercatinib Sensitive: C3 – Early Trials
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
selpercatinib Sensitive: C3 – Early Trials
|
selpercatinib Sensitive: C3 – Early Trials
|
RET V804L
|
Thyroid Gland Medullary Carcinoma
|
RET V804L
|
Thyroid Gland Medullary Carcinoma
|
selpercatinib Sensitive: C3 – Early Trials
|
selpercatinib Sensitive: C3 – Early Trials
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET inhibitor Sensitive: C3 – Early Trials
|
RET inhibitor Sensitive: C3 – Early Trials
|
RET V804M + RET M918T + RET G810 + RET Y806
|
Thyroid Gland Medullary Carcinoma
|
RET V804M + RET M918T + RET G810 + RET Y806
|
Thyroid Gland Medullary Carcinoma
|
selpercatinib Resistant: C4 – Case Studies
|
selpercatinib Resistant: C4 – Case Studies
|
NF1 mutation
|
Thyroid Gland Medullary Carcinoma
|
NF1 mutation
|
Thyroid Gland Medullary Carcinoma
|
vandetanib Sensitive: C4 – Case Studies
|
vandetanib Sensitive: C4 – Case Studies
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
everolimus + vandetanib Sensitive: C4 – Case Studies
|
everolimus + vandetanib Sensitive: C4 – Case Studies
|
ATM S978fs*12
|
Thyroid Gland Medullary Carcinoma
|
ATM S978fs*12
|
Thyroid Gland Medullary Carcinoma
|
everolimus + vandetanib Sensitive: C4 – Case Studies
|
everolimus + vandetanib Sensitive: C4 – Case Studies
|
ATM L804fs*4
|
Thyroid Gland Medullary Carcinoma
|
ATM L804fs*4
|
Thyroid Gland Medullary Carcinoma
|
everolimus + vandetanib Sensitive: C4 – Case Studies
|
everolimus + vandetanib Sensitive: C4 – Case Studies
|
RET C620R
|
Thyroid Gland Medullary Carcinoma
|
RET C620R
|
Thyroid Gland Medullary Carcinoma
|
everolimus Sensitive: C4 – Case Studies
|
everolimus Sensitive: C4 – Case Studies
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
everolimus Sensitive: C4 – Case Studies
|
everolimus Sensitive: C4 – Case Studies
|
RET C618R
|
Thyroid Gland Medullary Carcinoma
|
RET C618R
|
Thyroid Gland Medullary Carcinoma
|
sorafenib Sensitive: C4 – Case Studies
|
sorafenib Sensitive: C4 – Case Studies
|
RET C634F
|
Thyroid Gland Medullary Carcinoma
|
RET C634F
|
Thyroid Gland Medullary Carcinoma
|
sorafenib Sensitive: C4 – Case Studies
|
sorafenib Sensitive: C4 – Case Studies
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
vandetanib Sensitive: C4 – Case Studies
|
vandetanib Sensitive: C4 – Case Studies
|
ATM S978fs*12
|
Thyroid Gland Medullary Carcinoma
|
ATM S978fs*12
|
Thyroid Gland Medullary Carcinoma
|
vandetanib Sensitive: C4 – Case Studies
|
vandetanib Sensitive: C4 – Case Studies
|
ATM L804fs*4
|
Thyroid Gland Medullary Carcinoma
|
ATM L804fs*4
|
Thyroid Gland Medullary Carcinoma
|
vandetanib Sensitive: C4 – Case Studies
|
vandetanib Sensitive: C4 – Case Studies
|
RET L629P
|
Thyroid Gland Medullary Carcinoma
|
RET L629P
|
Thyroid Gland Medullary Carcinoma
|
pralsetinib Sensitive: C4 – Case Studies
|
pralsetinib Sensitive: C4 – Case Studies
|
RET D631_R635delinsG
|
Thyroid Gland Medullary Carcinoma
|
RET D631_R635delinsG
|
Thyroid Gland Medullary Carcinoma
|
pralsetinib Sensitive: C4 – Case Studies
|
pralsetinib Sensitive: C4 – Case Studies
|
RET V637R
|
Thyroid Gland Medullary Carcinoma
|
RET V637R
|
Thyroid Gland Medullary Carcinoma
|
pralsetinib Sensitive: C4 – Case Studies
|
pralsetinib Sensitive: C4 – Case Studies
|
RET exon 11 deletion
|
Thyroid Gland Medullary Carcinoma
|
RET exon 11 deletion
|
Thyroid Gland Medullary Carcinoma
|
sorafenib + tipifarnib Sensitive: C4 – Case Studies
|
sorafenib + tipifarnib Sensitive: C4 – Case Studies
|
RET V804M + M918T
|
Thyroid Gland Medullary Carcinoma
|
RET V804M + M918T
|
Thyroid Gland Medullary Carcinoma
|
selpercatinib Sensitive: C4 – Case Studies
|
selpercatinib Sensitive: C4 – Case Studies
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
sunitinib Sensitive: C4 – Case Studies
|
sunitinib Sensitive: C4 – Case Studies
|
RET Y900_S904delinsP
|
Thyroid Gland Medullary Carcinoma
|
RET Y900_S904delinsP
|
Thyroid Gland Medullary Carcinoma
|
selpercatinib Sensitive: C4 – Case Studies
|
selpercatinib Sensitive: C4 – Case Studies
|
CCDC6-ALK fusion
|
Thyroid Gland Medullary Carcinoma
|
CCDC6-ALK fusion
|
Thyroid Gland Medullary Carcinoma
|
alectinib Sensitive: C4 – Case Studies
|
alectinib Sensitive: C4 – Case Studies
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
RAF265 Sensitive: D – Preclinical
|
RAF265 Sensitive: D – Preclinical
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
AMG 706 Resistant: D – Preclinical
|
AMG 706 Resistant: D – Preclinical
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
AMG 706 Resistant: D – Preclinical
|
AMG 706 Resistant: D – Preclinical
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
lenvatinib Sensitive: D – Preclinical
|
lenvatinib Sensitive: D – Preclinical
|
KRAS G12R
|
Thyroid Gland Medullary Carcinoma
|
KRAS G12R
|
Thyroid Gland Medullary Carcinoma
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
BRAF mutation
|
Thyroid Gland Medullary Carcinoma
|
BRAF mutation
|
Thyroid Gland Medullary Carcinoma
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
PTEN mutation
|
Thyroid Gland Medullary Carcinoma
|
PTEN mutation
|
Thyroid Gland Medullary Carcinoma
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
NRAS mutation
|
Thyroid Gland Medullary Carcinoma
|
NRAS mutation
|
Thyroid Gland Medullary Carcinoma
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
KRAS mutation
|
Thyroid Gland Medullary Carcinoma
|
KRAS mutation
|
Thyroid Gland Medullary Carcinoma
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
cabozantinib capsule Sensitive: D – Preclinical
|
cabozantinib capsule Sensitive: D – Preclinical
|
BRAF V600E
|
Thyroid Gland Medullary Carcinoma
|
BRAF V600E
|
Thyroid Gland Medullary Carcinoma
|
CI-1040 Sensitive: D – Preclinical
|
CI-1040 Sensitive: D – Preclinical
|
RET C634Y
|
Thyroid Gland Medullary Carcinoma
|
RET C634Y
|
Thyroid Gland Medullary Carcinoma
|
sorafenib Sensitive: D – Preclinical
|
sorafenib Sensitive: D – Preclinical
|